PULSE BIOSCIENCES, INC. 8-K

What Happened
Pulse Biosciences, Inc. (PLSE) filed an 8-K on April 16, 2026 disclosing that it posted an updated investor presentation on its website. The Investor Deck (attached as Exhibit 99.1) provides new details about the company’s pivotal clinical study of its nsPFA cardiac catheter to treat atrial fibrillation, describes the next‑generation nPulse cardiac catheter under development, and summarizes the company’s 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation. The company said it expects to use the deck, in whole or in part, in presentations to investors, analysts and others.

Key Details

• Filing date: April 16, 2026 (Form 8-K, Item 7.01; Exhibit 99.1 Investor Deck).
• Main topics disclosed: pivotal clinical study of nsPFA cardiac catheter for atrial fibrillation, next‑generation nPulse cardiac catheter development, and 2026 corporate goals in electrophysiology, cardiac surgery and soft tissue ablation.
• Disclosure made under Regulation FD and the presentation may be used in future investor/analyst presentations.

Why It Matters
This filing gives investors direct, company‑provided detail about clinical and product development progress in Pulse’s cardiac electrophysiology programs. The updated investor deck is a primary source for assessing near‑term milestones and strategic focus areas (clinical study plans and next‑gen device development) that may drive future corporate updates. Because the disclosure is public and intended for investor/analyst use, it ensures broad access to the company’s latest program status and goals.